No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
CRNX241220C90000
- 0.00
- 0.000.00%
15min DelayClose Dec 12 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest90.00Strike Price0.00Turnover0.00%IV61.81%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Crinetics Pharmaceuticals Grants Stock Options to New Employees Under 2021 Inducement Plan
Express News | Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
JMP Securities Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $87
Express News | Crinetics Pharmaceuticals Inc - FDA Targets Pdufa Date Sept 25, 2025 for Nda Review Completion
Express News | Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients With Acromegaly